Cystic Fibrosis Therapeutics Market to Grow Substantially by 2029 - Brandessence Market Research
Comunicato Precedente
Comunicato Successivo
Key Takeaways
The Global Cystic Fibrosis Therapeutics Market is valued at USD 10.74 Billion in 2022 and is expected to reach USD 30.71 Billion by 2029 with a CAGR of 16.2% over the forecast period.
Get Sample of Report@ https://brandessenceresearch.com/downloadSample/PostId/2590
Key Trends and Dynamics of Global Cystic Fibrosis Market
Increasing prevalence and diagnosis of cystic fibrosis, along with rising popularity of personalized medicine and targeted therapies are augmenting the outlook of this market. Also, growing investment in research and development for cystic fibrosis therapeutics is another growth propellant for this market. Besides, supportive government policies, and rising awareness among healthcare professionals are creating lucrative opportunities for this industry vertical to prosper.
Major Growth Drivers
Growing popularity of personalized medicines: The growing trend towards personalized medicine is another significant driver in the cystic fibrosis therapeutics market. With advancements in genetic testing and understanding of specific CF mutations, there is a shift towards tailoring treatments to individual patients. This approach allows for more targeted therapies and better treatment outcomes, driving the demand for personalized cystic fibrosis therapeutics and fuelling market growth.
Rising Awareness and Diagnosis Rates: Increasing awareness about cystic fibrosis and improved diagnostic techniques have led to higher diagnosis rates globally. As more cases of cystic fibrosis are identified, the demand for effective therapeutics rises correspondingly. This increased awareness and early diagnosis contribute to market growth as patients seek appropriate treatments and management strategies to improve their quality of life.
Challenges
Expensive treatment costs- One of the major challenges in the cystic fibrosis therapeutics market is the high cost associated with the treatment. The development and production of innovative therapies, such as CFTR modulators, involve significant research and investment. As a result, these therapies often come with a hefty price tag, posing financial barriers for patients and healthcare systems. Access to affordable cystic fibrosis therapeutics remains a challenge, hindering widespread adoption and potentially limiting patient outcomes.
Competitive Landscape of Cystic Fibrosis Therapeutics Market
The prominent players defining the competitive terrain of this business sphere are AbbVie Inc., Gilead Sciences, Novartis International AG, Vertex Pharmaceuticals Incorporated, Proteostasis Therapeutics, Mylan N.V., Hoffmann-La Roche Ltd., Sanofi S.A., Galapagos NV, Chiesi Farmaceutici S.p.A., Savara Inc., Translate Bio Inc., Kamada Ltd., Alaxia SAS, Celtaxsys, Insmed Incorporated, and Others.
Segmental Assessment
By drug class, the antibiotics segment is reckoned to amass notable gains over 2022-2029 since antibiotics are essential in treating and preventing these infections, thereby improving lung function and overall patient health.
Based on route of administration, the inhaled drugs segment is anticipated to showcase significant returns. This is credited to the targeted delivery of inhaled drugs to the lungs, convenience for patients, localized effects, and advancements in inhalation technology.
Get Methodology @ https://brandessenceresearch.com/requestMethodology/PostId/2590
Geographical Analysis & Landscape
The cystic fibrosis therapeutics market in the Middle East and Africa (MEA) region is experiencing steady growth due to the rising cognizance and improved diagnosis of cystic fibrosis, advancements in medical infrastructure, along with increased medical expenditure. Furthermore, presence of prominent players, rising R&D investments, along with technological advancements in the field are adding traction to the growth of this regional market.
Europe is reckoned to emerge as one of the fastest growing regions in this industry. This is attributable to the rapidly evolving healthcare infrastructure, rising prevalence of the target ailments, and presence of favourable healthcare reimbursement scenario.
Opportunities
Advancements in CFTR Modulators: The development and increasing availability of CFTR modulators have emerged as a major growth driver in the cystic fibrosis therapeutics market. These innovative therapies aim to correct the underlying genetic mutations responsible for cystic fibrosis, leading to improved lung function and overall patient outcomes. Ongoing research and development efforts in this area are expected to drive market growth by offering more effective and personalized treatment options.
Major Developments in Cystic Fibrosis Therapeutics Market
In 2019, AbbVie announced the acquisition of Allergen with an aim to diversify its portfolio and expand its presence in this industry.
In 2021, Vertex Pharmaceuticals announced the acquisition of Semma Therapeutics with an aim to strengthen its position in the field of regenerative medicine and expands its pipeline of innovative therapies for cystic fibrosis.
In 2019, Galapagos NV, a biotechnology company, entered into a partnership with Gilead Sciences, a leading pharmaceutical company. The partnership aims to develop and commercialize novel therapies for various diseases, including cystic fibrosis.
Porter's Five Forces Analysis
Threat of New Entrants: The threat of new entrants into the cystic fibrosis therapeutics market is relatively low. Developing new therapies for cystic fibrosis requires significant investment in research and development, clinical trials, and regulatory approvals. Additionally, existing players in the market have established strong expertise, intellectual property rights, and distribution networks. These factors create barriers to entry, making it challenging for new entrants to compete effectively.
Bargaining Power of Buyers: The bargaining power of buyers in the cystic fibrosis therapeutics market is moderate. Buyers, such as healthcare providers and patients, seek effective treatments at reasonable prices. However, the limited number of available therapies for cystic fibrosis and the critical nature of these treatments give pharmaceutical companies some leverage. Buyers often rely on these companies to provide life-saving medications, reducing their bargaining power to some extent.
Bargaining Power of Suppliers: The bargaining power of suppliers in the cystic fibrosis therapeutics market is moderate to high. Suppliers of key components, such as active pharmaceutical ingredients (APIs), play a crucial role in the manufacturing of therapeutics. Pharmaceutical companies depend on reliable and quality supplies to develop their products. However, if there are limited suppliers or a shortage of critical materials, suppliers can exert significant influence and negotiate favourable terms.
Threat of Substitutes: The threat of substitutes in the cystic fibrosis therapeutics market is relatively low. Cystic fibrosis is a complex genetic disorder with limited alternative treatment options. While supportive therapies and treatments can help manage symptoms, there are no direct substitutes that can address the underlying cause of the disease. This lack of viable substitutes strengthens the position of existing cystic fibrosis therapeutics in the market.
Competitive Rivalry: The intensity of competitive rivalry in the cystic fibrosis therapeutics market is high. The market is dominated by a few major pharmaceutical companies that have developed and commercialized CFTR modulators and other targeted therapies. Competition is driven by factors such as drug efficacy, safety profiles, pricing strategies, market access, and ongoing research and development efforts. Continuous innovation and the pursuit of market exclusivity create a competitive environment within the cystic fibrosis therapeutics market.
On Special Requirement Acute Repetitive Seizures Market Report is also available for below region:
Purchase Copy of Report @ https://brandessenceresearch.com/Checkout?report_id=2590
Related Reports:
Report Forecasts Promising Future for U.S. Home Infusion Therapy Market with New Therapeutic Approaches | Brandessence Market Research
Brandessence Market Research & Consulting Pvt ltd.
Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Follow Us: Linkedin
M & A Advisory: Merger & Acquisition, and Capabilities
Blog:
What is Market Research?
What is Market Sizing? How to Measure Your TAM, SAM, and SOM
Contact:
Mr. Vishal Sawant
Email: vishal@brandessenceresearch.com
Email: Sales@brandessenceresearch.com
Corporate Sales: +44-2038074155
Asia Office: +917447409162
Logo: https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cystic-fibrosis-therapeutics-market-to-grow-substantially-by-2029---brandessence-market-research-301828552.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
